XRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
XORTX Therapeutics Inc (XRTX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The lack of strong positive catalysts, poor financial performance, and absence of clear trading signals suggest holding off on this investment for now.
The MACD is positive and expanding, indicating a mild bullish momentum. However, the RSI is neutral at 65.486, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels at 0.446 and 0.474 suggest limited upward potential in the short term.
The company is advancing three clinically advanced products for kidney disease treatment and is focused on developing therapies for gout patients. Confidence in future product development is noted.
The company announced a share consolidation, which may signal financial instability or a need to meet listing requirements. Financial performance is severely negative, with a significant drop in net income (-581.87% YoY) and EPS (-325.00% YoY). Regulatory and clinical trial risks are also highlighted.
In Q4 2025, revenue remained at 0 with no growth. Net income dropped significantly to -590,462 (-581.87% YoY), and EPS fell to -0.09 (-325.00% YoY). Gross margin remained at 0 with no improvement.
No analyst rating or price target data available.
